Crohn Disease Clinical Trial
— PANACEAPILOTOfficial title:
PAtophysiological, Nodal-based Approach for Crohn's Disease Excision: A PILOT Study
Single centre prospective pilot study on surgery for Crohn's disease (CD). CD universally recurs after surgery and no technique so far has been proven to reduce recurrence. The investigators speculate that a different surgical technique, based on pathophysiology of the disease may prove successful in reducing rates of recurrence. Consecutive CD patients with a surgical indication for ileocolic disease will receive an extended procedure including a lymphadenectomy (Pathophysiologic excision for Crohn's disease). Primary outcome will be endoscopic recurrence rates at 6 and 12 months from surgery.
Status | Recruiting |
Enrollment | 12 |
Est. completion date | April 30, 2021 |
Est. primary completion date | April 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All consecutive patients undergoing surgery for ileocaecal/ileocolic CD in the Minimally Invasive Unit at Policlinico Tor Vergata are eligible to be enrolled. - Informed consent Exclusion Criteria: - Crohn's Disease with a different localisation - Recurrent disease - Extensive jejunitis - <18 years of age - Cancer as primary indication for surgery - Followed by gastroenterologists outside our centre, due to loss of follow up - Ileostomy. If a patient undergoes ileostomy fashioning he will be excluded from the study and this will be reported |
Country | Name | City | State |
---|---|---|---|
Italy | Policlinico Tor Vergata | Roma | RM |
Lead Sponsor | Collaborator |
---|---|
University of Rome Tor Vergata |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of endoscopic CD recurrence | Endoscopic Rutgeerts score >1 | 6 months | |
Primary | Rate of endoscopic CD recurrence | Endoscopic Rutgeerts score >1 | 12 months | |
Secondary | Rate of overall postoperative complications | Clavien Dindo I-V | 30 days | |
Secondary | Rate of major postoperative complications | Clavien Dindo III-V | 30 days | |
Secondary | Overall and Disease specific Quality of life | Inflammatory Bowel Disease Questionnaire (32 to 224 with higher scores representing better quality of life) | 6 months | |
Secondary | Overall and Disease specific Quality of life | Inflammatory Bowel Disease-Control (Q 1-3 with higher scores representing better quality of life) | 6 months | |
Secondary | Overall and Disease specific Quality of life | Cleveland Global Quality of Life score (0-1 with with higher scores representing better quality of life) | 6 months | |
Secondary | Overall and Disease specific Quality of life | Inflammatory Bowel Disease Questionnaire (32 to 224 with higher scores representing better quality of life) | 12 months | |
Secondary | Overall and Disease specific Quality of life | Inflammatory Bowel Disease-Control Q1-3 (0-18 with higher scores representing better quality of life) | 12 months | |
Secondary | Overall and Disease specific Quality of life | Cleveland Global Quality of Life score (0-1 with higher scores representing better quality of life) | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Recruiting |
NCT05169593 -
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
|
Phase 4 | |
Recruiting |
NCT06116604 -
Early Bowel Resection for Terminal Ileal Crohn's Disease
|
||
Recruiting |
NCT05294107 -
Intestinal Organoids
|
N/A | |
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT05627128 -
A Culturally Tailored Dietary Intervention to Treat Crohn's Disease
|
N/A | |
Withdrawn |
NCT04349449 -
ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
|
||
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT03058679 -
Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
|
N/A | |
Completed |
NCT02871635 -
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
|
Phase 3 | |
Recruiting |
NCT04539665 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.
|
N/A | |
Recruiting |
NCT04266600 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease
|
N/A | |
Recruiting |
NCT03913572 -
Treatment of Perianal Disease Using Adipose-derived Stem Cells
|
||
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Terminated |
NCT04102111 -
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
|
Phase 2 | |
Recruiting |
NCT04997733 -
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
|
Phase 3 | |
Recruiting |
NCT05906576 -
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
|
Phase 4 | |
Not yet recruiting |
NCT04502303 -
18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease
|
Phase 2 | |
Not yet recruiting |
NCT04398836 -
Preoperative Nutrition for Crohn's Disease Patients
|
Phase 3 |